

Regenerative Medicine Expert Group (RMEG)

Terms of Reference

1. The Regenerative Medicine Expert Group (RMEG) will consist of key individuals and organisations in the field of regenerative medicine. In particular those with key expertise in its delivery in the NHS, regulation, those developing regenerative medicines both in the academic and the industrial sector, and representatives from medical charities to provide a patient perspective within the work of the Group.
2. It will develop an NHS regenerative medicine delivery readiness strategy and action plan, drawing on existing initiatives and will build on these so that the NHS is fully prepared to deliver these innovative treatments.
3. The strategy will cover the operational delivery of regenerative medicines, which will include manufacturing, storing, transporting and administering of these medicines. The Group will also provide advice and recommendations on the evaluation and commissioning pathway (including reimbursement) and its application for the adoption of regenerative medicines in the NHS.
4. RMEG will also assess and report on the effect of regulation on the development of regenerative medicines in the UK, addressing any concerns where possible.
5. The Group will report its strategy and action plan to the Secretary of State for Health by December 2014.
6. The Group may commission other bodies or individuals to conduct research or provide papers to RMEG for consideration and decision making.